[ad_1]
The publication of a manuscript entitled HIV / AIDS vaccines: 2018, was announced by GeoVax Labs, Inc., a biotechnology company developing human vaccines.
The manuscript was written by Harriet L. Robinson, Ph.D., director of HIV vaccines and emeritus scientist at GeoVax, and published in a peer-reviewed journal. Clinical and therapeutic pharmacology.
In this article, Dr. Robinson describes in detail the progress made in the development of an HIV / AIDS vaccine, including key issues and lessons learned from completed efficacy trials.
Despite the development of effective antiretroviral (ARV) therapies, about 48% of people living with the human immunodeficiency virus (HIV) in the United States and around the world suffer from controlled infections.
The HIV virus infected 76 million people and killed around 35 million people.
Patients uninfected by controlled drugs not only develop AIDS, but also spread the infection, GeoVax said in a press release.
These data indicate that, for the elimination of HIV, it is necessary to add an effective vaccine to the arsenal of antiretroviral therapy.
The prevention of infection is best ensured by a neutralizing antibody (Ab) blocking the entry of the virus into a cell.
Progress has also been made towards a vaccine, although it has not yet delivered a licensed product.
The development of an HIV vaccine faces many challenges, including:
- the life cycle of the virus, which promotes the rapid establishment of chronic infections difficult to eliminate,
- the high diversity and structure of the envelope glycoprotein limiting the ability to generate large scale neutralizing antibodies (bnAb), and
- the tropism of the virus for helper T cells facilitating infection, spread and persistence.
"Only with an effective and proven HIV / AIDS vaccine can people around the world avoid infection, the health risks that persist and the societal impact of the disease," he said. GeoVax.
GeoVax's HIV vaccine candidate, GOVX-B11, is currently making progress in human clinical trials with sponsorship from the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.
The GOVX-B11 vaccine has been tested at different doses and regimens in clinical trials involving approximately 500 participants. In these trials, the vaccine was extremely well tolerated.
Click here for more information on GeoVax vaccine development.
Source link
